Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03046953 · FLOW

Participant flow

Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma · Source last updated 2024-07-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients received Avelumab 10mg/kg by IV infusion once every 2 weeks. A maximum of 8 cycles, each cycle is 28 days. Avelumab: anti-PDL1 antibody
    id
    FG000
    title
    Avelumab
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        21
      type
      Relapse/progressive disease
    2. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Withdrawal by Subject
    milestones
    1. achievements
      1. comment
        Of the 35 patients registered on the trial, only 32 actually started treatment.
        group Id
        FG000
        num Subjects
        32
      type
      STARTED
    2. achievements
      1. comment
        16 patients completed cycle 3 with disease assessments done and so were evaluable
        group Id
        FG000
        num Subjects
        16
      comment
      Patients had to reach the CT scan assessment for cycle 3 to be evaluable for the trial
      type
      Completed Cycle 3
    3. achievements
      1. comment
        10 patients completed cycle 6, 9 disease assessments done, one disease assessment not done
        group Id
        FG000
        num Subjects
        10
      type
      Completed Cycle 6
    4. achievements
      1. comment
        6 patients completed cycle 8, 4 disease assessments done, 2 disease assessments not done
        group Id
        FG000
        num Subjects
        6
      type
      Completed Cycle 8
    5. achievements
      1. group Id
        FG000
        num Subjects
        6
      type
      COMPLETED
    6. achievements
      1. group Id
        FG000
        num Subjects
        26
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Of 35 enrolled patients, only 32 started treatment. Of the 3 patients who did not start treatment, one died, one relapsed and one was found to be ineligible post registration.
recruitment Details
Patient were recruited from November 14, 2017 to November 18, 2019 at 14 UK (United Kingdom) hospitals by clinician referral. The first patient was recruited on December 8, 2017, and the final patient recruited on November 18, 2019.
Complete source fields
groups
  1. description
    Patients received Avelumab 10mg/kg by IV infusion once every 2 weeks. A maximum of 8 cycles, each cycle is 28 days. Avelumab: anti-PDL1 antibody
    id
    FG000
    title
    Avelumab
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        21
      type
      Relapse/progressive disease
    2. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Withdrawal by Subject
    milestones
    1. achievements
      1. comment
        Of the 35 patients registered on the trial, only 32 actually started treatment.
        group Id
        FG000
        num Subjects
        32
      type
      STARTED
    2. achievements
      1. comment
        16 patients completed cycle 3 with disease assessments done and so were evaluable
        group Id
        FG000
        num Subjects
        16
      comment
      Patients had to reach the CT scan assessment for cycle 3 to be evaluable for the trial
      type
      Completed Cycle 3
    3. achievements
      1. comment
        10 patients completed cycle 6, 9 disease assessments done, one disease assessment not done
        group Id
        FG000
        num Subjects
        10
      type
      Completed Cycle 6
    4. achievements
      1. comment
        6 patients completed cycle 8, 4 disease assessments done, 2 disease assessments not done
        group Id
        FG000
        num Subjects
        6
      type
      Completed Cycle 8
    5. achievements
      1. group Id
        FG000
        num Subjects
        6
      type
      COMPLETED
    6. achievements
      1. group Id
        FG000
        num Subjects
        26
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Of 35 enrolled patients, only 32 started treatment. Of the 3 patients who did not start treatment, one died, one relapsed and one was found to be ineligible post registration.
recruitment Details
Patient were recruited from November 14, 2017 to November 18, 2019 at 14 UK (United Kingdom) hospitals by clinician referral. The first patient was recruited on December 8, 2017, and the final patient recruited on November 18, 2019.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice